Message from President
Corporate Information
Access to Medicines
Corporate Governance
Japan Business Sites
Production and Logistics
Marketing
News Releases
Corporate Philosophy
What is hhc?
Compliance
Message to Stakeholders
Eisai's Views on Environmental Issues
Environmental and Social Report
Social Contribution Activities
Potential Suppliers
Business Performance Highlights
Financial Information
Presentations
Annual Report
IR Calendar
Analyst Coverage
Investor Kit
Share Information
Bonds and Ratings
IR Site Map
Investors
1 Minute Guide to 4 Key Points
1. Understanding Products
2. Understanding Strengths
3. Understanding Research and Development
4. Understanding Business Results
Introduction to Eisai Shares
Understanding the Pharmaceutical Industry
Eisai Glossary
Understanding Eisai Sitemap
Home
>
Investors
>
Understanding Eisai
>
Eisai Glossary
Introducing expressions used in Understanding Eisai.
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Eisai product names
New Eisai pharmaceuticals under development
Eisai's businesses
Pharmaceuticals/treatments
Accounting
Acetylcholin-esterase inhibitor
AcipHex®
Actonel®
Aloxi®
ANDA
Aricept®
Back to Top
Blockbuster
Branded drug
Back to Top
Cash Income
Compliance
Compound (of matter) patent
Back to Top
Dacogen®
DOE
Drug price
Back to Top
E2007
E2012
E5564
E7389
European Knowledge Centre
Back to Top
Gasmotin®
Generics
Glufast®
Back to Top
Humira®
In Process R&D Expenses
Independent Marketing
Inovelon®
Back to Top
Managed care
Medicaid
Medicare
MGI Pharma, Inc.
Monoclonal antibody
Morphotek
MR
Back to Top
NeuroBloc®
NHI (National Health Insurance) drug price revision
NICE
NME
Back to Top
Off-label use
OTC
Back to Top
Pariet®
Pipeline
Placebo
Plan “HAYABUSA”
POC
Prialt®
Prescription pharmaceuticals
Proton pump inhibitor (PPI)
Psoriasis
Back to Top
QOL
Back to Top
Royalty
Seamless value chain
Sensitivity to currency
Stronger Neo-Minophagen® C
Switch OTC
Back to Top
TNF-alpha
T-614
Back to Top
Unmet medical needs
Back to Top
Zonegran®
Back to Top
AcipHex®
Actonel®
Aloxi®
Aricept®
Dacogen®
Gasmotin®
Glufast®
Humira®
Inovelon®
NeuroBloc®
Pariet®
Prialt®
Stronger Neo-Minophagen® C
Zonegran®
Back to Top
E2007
E2012
E5564
E7389
T-614
Back to Top
European Knowledge Centre
Independent Marketing
MGI Pharma, Inc.
Morphotek
Plan “HAYABUSA”
Seamless value chain
Back to Top
Acetylcholin-esterase inhibitor
ANDA
Blockbuster
Branded drug
Compliance
Compound (of matter) patent
Drug price
Generics
Managed care
Medicaid
Medicare
Monoclonal antibody
MR
NHI (National Health Insurance) drug price revision
NICE
NME
Off-label use
OTC
Pipeline
Placebo
POC
Prescription pharmaceuticals
Proton pump inhibitor (PPI)
Psoriasis
QOL
Switch OTC
TNF-alpha
Unmet medical needs
Back to Top
Cash Income
DOE
In Process R&D Expenses
Royalty
Sensitivity to currency
Understanding Eisai
Back to Top
Related Links
